lap and watching the stock market crash. there he goes. and a high drive. aaron judge his second home run of the game. he has got 57 now. oh, sometimes, i get a good feeling yeah. yeah. get a feeling that i never, never, never, never had before i get a good feel. ainsley: that is gorgeous. native amenarrow began zet rhod. i got shining down on the water narragansett, rhode island. that s what he saw from the santa maria, a bird flew in or leaves blew up and he realized he had land. ainsley: that s what noah saw every day for a long time. steve: 40 days. brian: that was a lot of rain. steve: maybe not every day had the shimmering sun that is just gorgeous. brian: imagine being on that ark with all those animals. ainsley: no. tigers come on in my house. brian: leave the donkey alone. steve: go at a time. ainsley: 79 degrees there. not a cloud in the sky according to the 10-day forecast. brian: and our eyes. ainsley: today at least and tomorro
Strasbourg, France, January 22, 2024, 5:45 p.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, is pleased to announce the appointment of James Wentworth, PhD, MBA, as Chief Business Officer (CBO) and member of the executive management team, effective immediately. Dr. Wentworth will be responsible for developing, leading, and implementing Transgene’s business, corporate development and partnering strategi
AC Immune’s Targeted Anti-pTau Active Immunotherapy for Alzheimer’s Disease Advances into Phase 2b Trial Potentially registration-enabling Phase 2b study (ReTain) will evaluate the effect of ACI-35.030 on cognition and Tau pathology in approximately 500 participants with preclinical Alzheimer’s disease (AD)Anti-pTau active immunotherapy being designed to potentially prevent or reduce cognitive decline could address need of over 315 million people globally1 with preclinical ADAC Immune to receive